advertisement
Humphries P 19
Showing records 1 to 19 | Display all abstracts from Humphries P108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
O'Callaghan J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Chadderton N; Palfi A
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Delaney C; O'Connor M
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Maloney DM
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
van Batenburg-Sherwood J; van Batenburg-Sherwood J
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Carrigan M; Finnegan LK
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Schicht M; Lütjen-Drecoll E
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Hanlon KS
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Hudson N
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Shortall C; O'Reilly M
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Ni Dhubhghaill S; Humphries P
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Humphries P; Cassidy L
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Stanley C
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Kenna PF
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Keravala A; Chalberg T
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Millington-Ward S
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Lawrence MS
Science advances 2023; 9: eadf6537
107916 Optimisation of AAV-NDI1 Significantly Enhances Its Therapeutic Value for Correcting Retinal Mitochondrial Dysfunction
Farrar GJ
Pharmaceutics 2023; 15:
108419 Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma
Campbell M
Science advances 2023; 9: eadf6537
